• Anti-Rabbit IgG (5B2): Evidence and Scope

  2026-10-15

  The APExBIO listing identifies MA4837 as a mouse monoclonal antibody directed against rabbit IgG, with clone designation 5B2. That naming supports an identity-level and conceptual mechanism overview, but the available product information does not document epitope, affinity, conjugation, validated applications, performance outcomes, or independent research use. The product should therefore be interpreted as a named immunochemical reagent rather than as a quantitatively validated assay component.

• IWP-L6: Documented Porcn Inhibition and Evidence Limits

  2026-10-14

  IWP-L6 is presented by APExBIO as a Porcn inhibitor that suppresses Wnt signaling by interfering with Porcn-dependent Wnt palmitoylation. The available evidence is catalog-level rather than an identity-matched research paper, so the reported potency, cellular readouts, developmental phenotypes, and stability claims should be interpreted as documented product information rather than independently verified performance.

• From Heart Fields to RV-Like Cardiomyocytes

  2026-10-14

  Saito et al. report a conceptual strategy for generating right-ventricular-like cardiomyocytes from human pluripotent stem cells by shifting cardiac progenitor identity toward the second heart field. The findings support chamber-specific differentiation as a proof of concept, while remaining limited by the in vitro model, marker-based classification, and the information available in the supplied study summary.

• SU 5402 and Human Neuronal HSV-1 Models

  2026-10-13

  SU 5402 is described by APExBIO as a multi-kinase inhibitor relevant to receptor tyrosine kinase signaling, cancer biology, and multiple myeloma research. However, the supplied 2025 study of human iPSC-derived sensory neurons did not evaluate SU 5402. Its findings support the model as a human-relevant system for examining HSV-1 latency and reactivation, but they do not establish a role for SU 5402, FGFR signaling, or other kinase pathways in that viral state.

• Polygodial and TRPA1: Evidence Boundaries

  2026-10-13

  A source-grounded assessment of what a 2024 nasal epithelial-cell study shows about TRPV1/TRPA1 signaling, and what remains unestablished about Polygodial as a TRPA1 channel activator.

• Dovitinib: Evidence, Scope, and Cancer Models

  2026-10-12

  Dovitinib (TKI-258) is described by its supplier as a multitargeted receptor tyrosine kinase inhibitor, but the supplied clinical-biology study concerns circulating cancer-associated macrophage-like cells rather than Dovitinib. The evidence therefore supports a cautious conceptual link between RTK signaling and tumor-associated phenotypes, not claims about efficacy, CAML biology, or clinical treatment.

• p38α Dephosphorylation and Dual-Action Inhibitors

  2026-10-12

  A 2024 bioRxiv preprint reports that three kinase inhibitors both inhibit p38α activity and increase WIP1-mediated dephosphorylation by favoring an activation-loop conformation that exposes the phospho-threonine. The work is mechanistically informative but remains provisional and does not establish clinical or disease-specific effects, nor does the supplied study summary identify Pexmetinib as one of the compounds tested.

• Epacadostat and Immunometabolic Evidence

  2026-10-11

  Epacadostat (INCB024360) is described by APExBIO as a selective IDO1 inhibitor, whereas the supplied Zhao et al. study evaluates standardized whole-blood immune stimulation under metabolic modulation. The study supports a conceptual link between metabolism and cytokine responses, but it does not directly test Epacadostat, IDO1 inhibition, tumors, or PD-1/PD-L1 combinations.

• Phenylmethanesulfonyl Fluoride: Evidence and Uses

  2026-10-10

  Phenylmethanesulfonyl fluoride (PMSF) is a covalent serine protease inhibitor used as a biochemical research tool. This overview distinguishes supplier-described mechanism and applications from disease-model evidence, explains its relevance to protein extraction and signaling studies, and outlines important limitations in selectivity, provenance, and interpretation.

• Tioconazole: Mechanism, Evidence, and Research Scope

  2026-10-09

  Tioconazole is an imidazole antifungal medication that disrupts fungal ergosterol biosynthesis through cytochrome P450 inhibition. Its product-specific formulation data support research use, while the supplied AML study provides a separate framework for interpreting energy stress and DNA-repair biology rather than evidence for Tioconazole in leukemia.

• Phenacetin: Research Context and Evidence Limits

  2026-10-09

  This overview separates supplier-reported information about Phenacetin from peer-reviewed evidence, explains its historical pharmacological context, and evaluates conceptual uses in pharmacokinetic studies. It also clarifies why findings from a PDK4 inhibitor study should not be interpreted as evidence about Phenacetin.

• Nystatin (Fungicidin): Evidence, Scope and Limits

  2026-10-08

  A source-grounded overview of how Nystatin works, what recent moxidectin combination research found, how strong the evidence is, and where the findings should not be generalized.

• Probenecid: Evidence, Applications, and Limits

  2026-10-08

  Probenecid, also known as 4-(dipropylsulfamoyl)benzoic acid, is studied as a modulator of organic anion transport, multidrug resistance-associated proteins, and pannexin-1 channels. Available evidence supports several biologically plausible research applications, but the supplied evidence is uneven: preclinical claims in leukemia and cerebral ischemia/reperfusion models should not be conflated with the separate 2024 study of CD28–ARS2–PKM signaling in CD8+ T cells.

• Dovitinib and the Hypoxic Tumor Microenvironment

  2026-10-07

  Dovitinib (TKI-258) offers a useful perturbation lens for studying how receptor tyrosine kinase signaling intersects with hypoxia, immunometabolism, and tumor-cell survival. This article distinguishes established pharmacology from emerging research hypotheses and outlines an evidence-aware framework for interpreting findings across cancer models.

• Perospirone: Neuropsychiatric and Vascular Evidence

  2026-10-07

  Perospirone is best understood as a receptor-active atypical antipsychotic with an emerging, experimentally defined vascular ion-channel signal. This overview separates established pharmacological context from the findings of a 2025 rabbit-cell study and explains why the Kv1.5 result is hypothesis-generating rather than proof of clinical cardiovascular effects.

7986 records 1/533 page Next 12345 下5页 Last page